Safety of Intranasal Irrigation Probiotics in Healthy Volunteers

Sinusitis Clinical Trial

Official title:

Safety of Intranasal Irrigation Probiotics in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02933918
• Other study ID #: PROB001
• Status: Completed
• Phase: N/A
• Start date: May 17, 2018
• Est. completion date: December 30, 2019

Study information

• Verified date: August 2019
• Source: Probionase Therapies Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Chronic rhinosinusitis (CRS) is one of the most common chronic diseases, affecting the quality of life of patients who suffer. Despite medical and surgical treatments available, there are a significant number of people suffering from CRS refractory to these standard treatments.

A preliminary clinical trial conducted at CHUM Hôtel-Dieu, has allowed us to evaluate the therapeutic potential of intranasal irrigation of probiotics in patients with CRS. This treatment administered twice daily for 14 days was well tolerated and resulted in improved chronic rhinosinusitis symptoms.

Prior to deployment on a larger scale, the safety of this therapy must be confirmed in a healthy population, free of sinus disease. Therefore, this study aims to assess the safety of the use of probiotic intranasal irrigation in healthy volunteers.

Description:

If the participant (healthy volunteer) agrees to participate in the study, and after signing the information consent form, her/his participation in this project will consist to receive the experimental treatment of probiotics, to come to four (4) medical assessment visits at CHUM, over a period of time of four (4) weeks, and answer to one (1) phone call.

This study will include five (5) periods :

1. Determination of eligibility period (Day 0)

2. Saline irrigation period (Day 0 to Day 7)

3. Elimination of saline period (Day 8 to Day 14)

4. Probiotic treatment period (Day 15 to Day 21)

5. Telephone follow-up period (Day 22 to Day 28)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: December 30, 2019
• Est. primary completion date: December 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Men and women aged 18 and older.

• Participant in general good health.

• Absence of nasal and ear signs or symptoms.

Exclusion Criteria:

• Participant suffering from acute rhinosinusitis, chronic rhinosinusitis, symptomatic allergic rhinitis, or other sinus disease.

• Participant with diseases of the middle ear causing impairment of the eardrum or middle ear, or have had surgery of the middle ear previously, except myringotomy with insertion tube.

• Primary or acquired immunodeficiencies documented.

• Antibiotic intake within 30 days before enrollment.

• Unable to do nasal rinse.

• Pregnant woman.

• Smell score from UPSIT-40 under normal smell threshold (<34).

Related Conditions & MeSH terms

• Sinusitis

Intervention

Other:
• Probiotics
Safety of nasal irrigation with probiotics in healthy volunteers

Locations

Country	Name	City	State
Canada	Centre Hospitalier de l'Université de Montréal	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Probionase Therapies Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in microbiome composition	Evaluation of the difference in the percentage of the bacterial population before and after treatment.	Change from baseline microbiome composition at Day 7 and Day 14
Primary	Change in sense of smell using the "University of Pennsylvania smell identification test (UPSIT-40)"	A smell test will be conducted using "scratch and sniff fragrance strips" (UPSIT-40), where 40 odors are presented. The participant must choose one of four choices for each odor, even if she/he is unable to identify the smell.	Change from baseline sense of smell at Day 7and Day 14
Secondary	Change in sino-nasal symptomatology using questionnaire	This questionnaire evaluates 5 items (nasal congestion, facial pain, headache, need to blow nose, post-nasal drip) on 0-3 scale (0= none; 1=mild; 2=moderate; 3= severe).	Change from baseline sino-nasal symptomatology at Day 7, Day 14 and Day 21
Secondary	Change in Eustachian tube symptomatology using a questionnaire of Eustachian Tube Dysfunction (ETDQ-7)	Using a questionnaire of Eustachian Tube Dysfunction (ETDQ-7).	Change from baseline Eustachian tube symptomatology at Day 7, Day 14 and Day 21
Secondary	Change in ear examination		Change from baseline ear examination at Day 7 and Day 14
Secondary	Change in anterior rhinoscopy		Change from baseline anterior rhinoscopy at Day 7 and Day 14